Device Firm Earnings Roundup
This article was originally published in The Gray Sheet
In this earnings review, we look at recent financial reports from Atricure, Greatbatch, Medtronic, Nevro and Endologix.
You may also be interested in...
The company says the Senza high-frequency system is the first spinal cord stimulator to be approved to claim superiority over existing spinal cord stimulation therapies. Approval is based on results of the highly touted SENZA-RCT trial.
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.
The device giant is recalling Cobalt and Crome defibrillators because they may deliver weaker shocks than intended.